191 related articles for article (PubMed ID: 35726602)
1. Mutation spectrum associated with metastasis of advanced cholangiocarcinoma.
Song H; Huang Y; Jiang X
J Int Med Res; 2022 Jun; 50(6):3000605221102080. PubMed ID: 35726602
[TBL] [Abstract][Full Text] [Related]
2. Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma.
Yang X; Lian B; Zhang N; Long J; Li Y; Xue J; Chen X; Wang Y; Wang Y; Xun Z; Piao M; Zhu C; Wang S; Sun H; Song Z; Lu L; Dong X; Wang A; Liu W; Pan J; Hou X; Guan M; Huo L; Shi J; Zhang H; Zhou J; Lu Z; Mao Y; Sang X; Wu L; Yang X; Wang K; Zhao H
BMC Med; 2024 Jan; 22(1):42. PubMed ID: 38281914
[TBL] [Abstract][Full Text] [Related]
3. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
[TBL] [Abstract][Full Text] [Related]
4. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.
Simbolo M; Fassan M; Ruzzenente A; Mafficini A; Wood LD; Corbo V; Melisi D; Malleo G; Vicentini C; Malpeli G; Antonello D; Sperandio N; Capelli P; Tomezzoli A; Iacono C; Lawlor RT; Bassi C; Hruban RH; Guglielmi A; Tortora G; de Braud F; Scarpa A
Oncotarget; 2014 May; 5(9):2839-52. PubMed ID: 24867389
[TBL] [Abstract][Full Text] [Related]
5. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
Churi CR; Shroff R; Wang Y; Rashid A; Kang HC; Weatherly J; Zuo M; Zinner R; Hong D; Meric-Bernstam F; Janku F; Crane CH; Mishra L; Vauthey JN; Wolff RA; Mills G; Javle M
PLoS One; 2014; 9(12):e115383. PubMed ID: 25536104
[TBL] [Abstract][Full Text] [Related]
6. Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay.
Arnold A; Bahra M; Lenze D; Bradtmöller M; Guse K; Gehlhaar C; Bläker H; Heppner FL; Koch A
Exp Mol Pathol; 2015 Oct; 99(2):344-53. PubMed ID: 26260902
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways.
Kongpetch S; Jusakul A; Ong CK; Lim WK; Rozen SG; Tan P; Teh BT
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):233-44. PubMed ID: 25966424
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of genomic alterations of Chinese hilar cholangiocarcinoma patients.
Feng F; Wu X; Shi X; Gao Q; Wu Y; Yu Y; Cheng Q; Li B; Yi B; Liu C; Hao Q; Zhang L; Gao C; Jiang X
Int J Clin Oncol; 2021 Apr; 26(4):717-727. PubMed ID: 33387086
[TBL] [Abstract][Full Text] [Related]
10. Molecular profiling and prognostic analysis in Chinese cholangiocarcinoma: an observational, retrospective single-center study.
Zhang C; You X; Zhang Q; Wang D
Invest New Drugs; 2024 Feb; 42(1):24-34. PubMed ID: 37975978
[TBL] [Abstract][Full Text] [Related]
11. Lymphoepithelioma-like Intrahepatic Cholangiocarcinoma Is a Distinct Entity With Frequent pTERT/TP53 Mutations and Comprises 2 Subgroups Based on Epstein-Barr Virus Infection.
Tsai JH; Liau JY; Lee CH; Jeng YM
Am J Surg Pathol; 2021 Oct; 45(10):1409-1418. PubMed ID: 33859071
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing.
Putra J; de Abreu FB; Peterson JD; Pipas JM; Mody K; Amos CI; Tsongalis GJ; Suriawinata AA
Exp Mol Pathol; 2015 Oct; 99(2):240-4. PubMed ID: 26189129
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
[TBL] [Abstract][Full Text] [Related]
14. Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis.
Goeppert B; Stichel D; Toth R; Fritzsche S; Loeffler MA; Schlitter AM; Neumann O; Assenov Y; Vogel MN; Mehrabi A; Hoffmann K; Köhler B; Springfeld C; Weichenhan D; Plass C; Esposito I; Schirmacher P; von Deimling A; Roessler S
Gut; 2022 Feb; 71(2):391-401. PubMed ID: 33468537
[TBL] [Abstract][Full Text] [Related]
15. Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
Dong LQ; Shi Y; Ma LJ; Yang LX; Wang XY; Zhang S; Wang ZC; Duan M; Zhang Z; Liu LZ; Zheng BH; Ding ZB; Ke AW; Gao DM; Yuan K; Zhou J; Fan J; Xi R; Gao Q
J Hepatol; 2018 Jul; 69(1):89-98. PubMed ID: 29551704
[TBL] [Abstract][Full Text] [Related]
16. ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer.
Lee SH; Cheon J; Lee S; Kang B; Kim C; Shim HS; Park YN; Jung S; Choi SH; Choi HJ; Lee CK; Chon HJ
Cancer Res Treat; 2023 Oct; 55(4):1291-1302. PubMed ID: 37139666
[TBL] [Abstract][Full Text] [Related]
17. Alterations in chemokine receptor CCR5 activity influence tumor cell biology in human cholangiocarcinoma cell lines.
Yang J; Sontag D; Gong Y; Minuk GY
Ann Hepatol; 2021; 21():100265. PubMed ID: 33045415
[TBL] [Abstract][Full Text] [Related]
18. Genomic and transcriptional alterations of cholangiocarcinoma.
Ito T; Sakurai-Yageta M; Goto A; Pairojkul C; Yongvanit P; Murakami Y
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):380-7. PubMed ID: 24532422
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker.
Utispan K; Thuwajit P; Abiko Y; Charngkaew K; Paupairoj A; Chau-in S; Thuwajit C
Mol Cancer; 2010 Jan; 9():13. PubMed ID: 20096135
[TBL] [Abstract][Full Text] [Related]
20. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
Montal R; Sia D; Montironi C; Leow WQ; Esteban-Fabró R; Pinyol R; Torres-Martin M; Bassaganyas L; Moeini A; Peix J; Cabellos L; Maeda M; Villacorta-Martin C; Tabrizian P; Rodriguez-Carunchio L; Castellano G; Sempoux C; Minguez B; Pawlik TM; Labgaa I; Roberts LR; Sole M; Fiel MI; Thung S; Fuster J; Roayaie S; Villanueva A; Schwartz M; Llovet JM
J Hepatol; 2020 Aug; 73(2):315-327. PubMed ID: 32173382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
